FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4210915759> ?p ?o ?g. }

• W4210915759 endingPage "1244" @default.
• W4210915759 startingPage "1238" @default.
• W4210915759 abstract "Objectives The aim of this study was to evaluate the safety and efficacy of cabergoline to control hypersomatotropism (HST) and diabetes mellitus (DM) in cats. Methods This was a prospective cohort study. Twenty-three cats with HST and concurrent DM were enrolled. Cats received a dose of 10 μg/kg cabergoline q48h PO for 6 months. Serum insulin-like growth factor 1 (IGF-1) and fructosamine concentrations, insulin dose and Insulin Resistance Index (IRI) were measured at the time of diagnosis of HST and at the start of cabergoline treatment (t0), and 3 months (t1) and 6 months (t2) during cabergoline treatment. Results A decrease and normalization of serum IGF-1 concentration was observed in 35% and 26% of cats, respectively. Median IGF-1 (t0: 1350 ng/ml [range 832–1501]; t1: 1284 ng/ml [range 365–1501]; t2: 1240 ng/ml [range 263–1501]; P = 0.016) decreased significantly. Twelve cats underwent diagnostic imaging of the pituitary area. The median pituitary height at t0 of cats that experienced an IGF-1 reduction (n = 5/12) was significantly lower compared with those that did not experience an IGF-1 reduction (n = 7/12) (3.2 mm [range 3.1–3.7] vs 6 mm [range 3.5–9.5]; P = 0.011). Median fructosamine (t0: 628 µmol/l [range 400–963]; t1: 404 µmol/l [range 249–780]; t2: 400 µmol/l [range 260–815]; P <0.0001), insulin dose (t0: 1.3 IU/kg [range 0.5–4.6]; t0: 0.5 IU/kg [range 0–2.3]; t2: 0.4 IU/kg [range 0–2.1]; P <0.0001) and IRI (t0: 800 µmolIU/kgl [range 257–2700]; t1: 300 µmolIU/kgl [range 0–1498]; t2: 250 µmolIU/kgl [range 0–1498]; P <0.0001) decreased significantly during cabergoline treatment. Eight cats achieved diabetic remission between months 1 and 6 of cabergoline treatment (median time to achieve remission: 3 months [range 1–6]). Three cats experienced asymptomatic hypoglycemia. Conclusions and relevance Cabergoline was effective in normalizing IGF-1 concentration in 26% of cats. Cabergoline improved diabetes control and was associated with remission of DM in 35% of cases. Cabergoline could be a treatment option for cats with HST and DM, especially in those cases with a relatively small pituitary tumor." @default.
• W4210915759 created "2022-02-09" @default.
• W4210915759 creator A5010036462 @default.
• W4210915759 creator A5036627208 @default.
• W4210915759 creator A5046211177 @default.
• W4210915759 creator A5054888457 @default.
• W4210915759 creator A5078625372 @default.
• W4210915759 creator A5082976237 @default.
• W4210915759 creator A5090619816 @default.
• W4210915759 date "2022-02-08" @default.
• W4210915759 modified "2023-10-14" @default.
• W4210915759 title "Cabergoline treatment in cats with diabetes mellitus and hypersomatotropism" @default.
• W4210915759 cites W1523183829 @default.
• W4210915759 cites W1912804428 @default.
• W4210915759 cites W1966863722 @default.
• W4210915759 cites W1980664585 @default.
• W4210915759 cites W1993154503 @default.
• W4210915759 cites W1994009654 @default.
• W4210915759 cites W2013030442 @default.
• W4210915759 cites W2014252560 @default.
• W4210915759 cites W2019477566 @default.
• W4210915759 cites W2027988039 @default.
• W4210915759 cites W2043132519 @default.
• W4210915759 cites W2047557486 @default.
• W4210915759 cites W2051176374 @default.
• W4210915759 cites W2081333049 @default.
• W4210915759 cites W2109220787 @default.
• W4210915759 cites W2120693758 @default.
• W4210915759 cites W2164875032 @default.
• W4210915759 cites W2196957770 @default.
• W4210915759 cites W2518308973 @default.
• W4210915759 cites W2585982923 @default.
• W4210915759 cites W2747014406 @default.
• W4210915759 cites W2756177891 @default.
• W4210915759 cites W2804607208 @default.
• W4210915759 cites W2884285576 @default.
• W4210915759 cites W2897430764 @default.
• W4210915759 cites W3045425869 @default.
• W4210915759 cites W3082594630 @default.
• W4210915759 cites W3132369514 @default.
• W4210915759 cites W3132399035 @default.
• W4210915759 cites W3174365678 @default.
• W4210915759 cites W4211191881 @default.
• W4210915759 doi "https://doi.org/10.1177/1098612x221074924" @default.
• W4210915759 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35133181" @default.
• W4210915759 hasPublicationYear "2022" @default.
• W4210915759 type Work @default.
• W4210915759 citedByCount "2" @default.
• W4210915759 countsByYear W42109157592022 @default.
• W4210915759 countsByYear W42109157592023 @default.
• W4210915759 crossrefType "journal-article" @default.
• W4210915759 hasAuthorship W4210915759A5010036462 @default.
• W4210915759 hasAuthorship W4210915759A5036627208 @default.
• W4210915759 hasAuthorship W4210915759A5046211177 @default.
• W4210915759 hasAuthorship W4210915759A5054888457 @default.
• W4210915759 hasAuthorship W4210915759A5078625372 @default.
• W4210915759 hasAuthorship W4210915759A5082976237 @default.
• W4210915759 hasAuthorship W4210915759A5090619816 @default.
• W4210915759 hasConcept C126322002 @default.
• W4210915759 hasConcept C134018914 @default.
• W4210915759 hasConcept C188816634 @default.
• W4210915759 hasConcept C2779064019 @default.
• W4210915759 hasConcept C2779306644 @default.
• W4210915759 hasConcept C2779832395 @default.
• W4210915759 hasConcept C2779904517 @default.
• W4210915759 hasConcept C2781357877 @default.
• W4210915759 hasConcept C555293320 @default.
• W4210915759 hasConcept C71315377 @default.
• W4210915759 hasConcept C71924100 @default.
• W4210915759 hasConcept C90924648 @default.
• W4210915759 hasConceptScore W4210915759C126322002 @default.
• W4210915759 hasConceptScore W4210915759C134018914 @default.
• W4210915759 hasConceptScore W4210915759C188816634 @default.
• W4210915759 hasConceptScore W4210915759C2779064019 @default.
• W4210915759 hasConceptScore W4210915759C2779306644 @default.
• W4210915759 hasConceptScore W4210915759C2779832395 @default.
• W4210915759 hasConceptScore W4210915759C2779904517 @default.
• W4210915759 hasConceptScore W4210915759C2781357877 @default.
• W4210915759 hasConceptScore W4210915759C555293320 @default.
• W4210915759 hasConceptScore W4210915759C71315377 @default.
• W4210915759 hasConceptScore W4210915759C71924100 @default.
• W4210915759 hasConceptScore W4210915759C90924648 @default.
• W4210915759 hasIssue "12" @default.
• W4210915759 hasLocation W42109157591 @default.
• W4210915759 hasLocation W42109157592 @default.
• W4210915759 hasOpenAccess W4210915759 @default.
• W4210915759 hasPrimaryLocation W42109157591 @default.
• W4210915759 hasRelatedWork W1983641721 @default.
• W4210915759 hasRelatedWork W1995945960 @default.
• W4210915759 hasRelatedWork W2026226896 @default.
• W4210915759 hasRelatedWork W2032033851 @default.
• W4210915759 hasRelatedWork W2041678535 @default.
• W4210915759 hasRelatedWork W2066345847 @default.
• W4210915759 hasRelatedWork W2089387278 @default.
• W4210915759 hasRelatedWork W2095179743 @default.
• W4210915759 hasRelatedWork W2124070488 @default.
• W4210915759 hasRelatedWork W2130904138 @default.
• W4210915759 hasVolume "24" @default.

• next